Guggenheim downgraded Arcturus Therapeutics (ARCT) to Neutral from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics Announces Phase 2 Trial Results
- Arcturus Therapeutics announces interim results from ARCT-032 trial
- Citi places ‘upside 90-day catalyst watch’ on Arcturus Therapeutics
- Arcturus Therapeutics Partners on New COVID-19 Vaccine Launch
- Cathie Wood Scales Back Roku and Roblox Stakes, Boosts Arcturus Holding